SCHEMBL2291985

SCHEMBL2291985

O=C(CON=C1CCN(S(=O)(=O)c2cccc(C(F)(F)F)c2)CC1)N1CCOCC1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.51
GAA P10253 3/20 0.48
EPHX2 P34913 1/20 0.47
LMNA P02545 2/20 0.47
PKM P14618 1/20 0.47
PKLR P30613 1/20 0.47
HTT P42858 2/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CNR1 P21554 1/20 0.46
F2 P00734 1/20 0.46
TSHR P16473 1/20 0.45
RECQL P46063 1/20 0.45
TP53 P04637 1/20 0.45
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2294261 0.88 CNR1 (0.50) KMT2AGAALMNAHTTHPGD
SCHEMBL2295401 0.88 CNR1 (0.50) KMT2AGAALMNAPKMPKLR
SCHEMBL3638556 0.88 KMT2A (0.43) KMT2AGAALMNAPKMHTT
SCHEMBL2297280 0.87 LMNA (0.47) GAALMNAPKMPKLRHTT
SCHEMBL2295472 0.85 LMNA (0.46) KMT2AGAALMNAPKMPKLR
SCHEMBL2297519 0.85 HTT (0.53) KMT2AGAALMNAPKMPKLR
SCHEMBL2298220 0.85 CNR1 (0.48) KMT2AGAALMNAHTTHPGD
SCHEMBL2292712 0.85 CNR1 (0.46) KMT2AGAALMNAPKMHTT
SCHEMBL2297070 0.84 SMN1; SMN2 (0.50) GAAEPHX2LMNAALDH1A1HSD17B10
SCHEMBL2290115 0.83 CNR1 (0.49) KMT2AGAALMNAHTTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2011-08-04 US disclosed
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2011-08-04 US disclosed
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2011-08-04 US disclosed
EP-2164326-A1 AMIDE COMPOUNDS AND THE USE THEREOF Euro-Celtique, S.A. (LU) 2010-03-24 EP disclosed
WO-2008150447-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2008-12-11 WO disclosed
WO-2008150447-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF CACNA1E, CACNA1B, CACNA1S KMT2A 2564/4885GAA 3413/4885EPHX2 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.